Michael Schelper’s Post

View profile for Michael Schelper, graphic

Growth Leader shaping the future of healthcare through technology | Board Member | Investor | Author | Keynote Speaker

🌟Strategic transformations are on the horizon for the #MedTech industry! As profitability declines due to high inflation, constrained capital markets, and geopolitical tensions, companies are shifting focus from top-line growth to profit maximization. Roland Berger reveals that 65% of industry leaders are now prioritizing EBITDA/profit over revenue growth, marking a significant shift in strategic priorities. This new approach involves simplifying portfolios and concentrating on core markets, aiming to stabilize core operations amidst the evolving business landscape. For investors, this shift signals on the one hand a more sustainable and resilient business model, positioned to withstand economic volatility and on the other hand opportunities for acquisitions, as business units parts / solutions are offloaded, which could be of high interest to portfolio companies. https://lnkd.in/e3YVguRS #MedTech #ProfitMaximization #StrategicShift #HealthcareInnovation Bjoern von Siemens Dennis Kogan Matt Krueger Amel Mokrani Bois Etienne Bauer Gargee Kashyap Emre kamil Özkan

Future of MedTech 2024

Future of MedTech 2024

rolandberger.com

Obaid AlMheiri

Driving Innovation and Investment in Life Sciences and Biotech | Leading Strategic Growth Initiatives at Abu Dhabi Investment Office

1mo

Michael Schelper , your emphasis on prioritizing EBITDA over rapid revenue growth echoes a broader industry trend where stabilizing core operations and maximizing profits are becoming paramount, especially in sectors crucial to economic growth like MedTech. This strategic focus not only promises more sustainable business models but also aligns with current shifts toward enhancing GDP contributions through innovative healthcare solutions. It’s a solid approach that seems well-suited for our times.

Very informative Mic. This will have a big impact on the Medtech industry, as it is expected that more start-ups and data driven innovations will rise in the next few years. This is also an immense opportunity for entrepreneurs who will be motivated by a potential acquisition, as part of their initial roadmap. Thank you for sharing these insights.

Very insightful! Profit is essential for MedTech companies to continue providing innovative and transformative technology. R&D, implementation, and other expenses come with significant costs that need to be covered, ultimately resulting in better patient outcomes. Thank you for sharing!

Vivek Patke

Business Development Executive @ SG Analytics | Sales, Strategy

1mo

Congratulations, Michael, on the exciting insights shared at Future of MedTech 2024! SG Analytics can further enhance innovation in MedTech through data-driven strategies and comprehensive market analysis.

See more comments

To view or add a comment, sign in

Explore topics